Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

Autor: Marshall, Alison D, Willing, Alex R, Kairouz, Abe, Cunningham, Evan B, Wheeler, Alice, O’Brien, Nicholas, Perera, Vidura, Ward, John W, Hiebert, Lindsey, Degenhardt, Louisa, Hajarizadeh, Behzad, Colledge, Samantha, Hickman, Matthew, Jawad, Danielle, Lazarus, Jeffrey V, Matthews, Gail V, Scheibe, Andrew, Vickerman, Peter, Dore, Gregory J, Grebely, Jason, Sargsyants, N., Suleymanova, L., Salkic, N., Simonova, M., Nemeth-Blazic, T., Mravcik, V., Kivimets, K., Salupere, R., Butsashvili, M., Soselia, G., Makara, M., Tolmane, I., Jancorienė, L., Stratulat, S., Flisiak, R., Gheorghe, L., Cernat, R., Lakhov, A., Stanevich, O., Jarcuska, P., Peck-Radosavljevic, M., Robaeys, G., Øvrehus, A., Foster, G., Sutinen, J., Farkkila, M., Rautiainen, H., Vuoti, S., Nikolova, D., Pawlotsky, J.M., Rockstroh, J., Sypsa, V., Papatheodoridis, G., Olafsson, S., Feeney, E., Teti, E., Seguin-Devaux, C., Pocock, J., Reiff, S., McDougall, N., Van der Valk, M., Dalgard, O., Tato Marinho, R., Dillon, J., Peters, E., Bojovic, K., Matičič, M., Kåberg, M., Bruggmann, P., Healy, B., Chong, V.H., Yi, S., Tucker, J., Pasaribu, L.R., Tanaka, J., Ashley, E.A., Abu Hassan, M.R., Mohammed, N.S., Chan, H.K., Gidaagaya, S., Kyi, K.P., Hyung Joon, K., Chin, B., Baladjay, P.C., Kao, J.H., Wansom, T., da Cruz, B., Flower, B., Ehsan, E., Al Mahtab, M., Khandu, L., Bhadoria, A.S., Alavi, M., KC, P., Hamid, S., Biryukov, S., Alymbaeva, D., Alaei, A., Bakieva, S., Flichman, D., Carmo, R.F., Valdez, E., Cortes, C.P., Contreras, F., Teran, E., Velez-Moller, P., Jagnarine, T., Mills, M., Goodman-Meza, D., Sánchez, J., Montenegro-Idrogo, J.J., Lugo Canales, A.M., Davy, J., Alexander, A., Gerona, S., Perazzo, R., Balak, D., Kelly-Hanku, A., Fineanganofo, A., Gane, E., Raymond, N., Debzi, N., Sridharan, K., Waked, I., Turner, D., Shibolet, O., Al Muzaini, A., El Nakib, M., Sheriff, D.S., Brahni, T., Essayagh, T., Essayagh, S., Hjaija, D., Al-Naamani, K., Sanai, F.M., Pasquale, H., Bedri, S., Chakroun, M., Ghrabi, A., Akarca, U.S., Falcao, V., Edmond Gbedo, S., Ouoba, S., Nyabenda, F., Rocher Mbella, M., Mahamat Moussa, A., Youssouf, T., Boniface, Y., Akilimali Shindano, T., Hamida, M.E., Mongo, A., Mapapa, C., Desalegn, H., Embinga, E.L.A., Ndow, G., Nartey, Y., Cisse, M., Djalo, M.A., Mugambi, M., Nyakowa, M., Jeuronlon, M.K., Ngoma, J., Manitrala Ramanampamonjy, R., Naik, K., Soyjaudah, M.D., Filipe, E., Nnakelu, E., Serumondo, J., Mbodj, M., Patino, M., Aalto, M.K., Waweru, P., Dagnra, A., Ocama, P., Maghimbi, A., Hamooya, B.M., Katsidzira, L., Rios, C., Thormann, M., Al Marzooqi, N., Al Rand, H.M., Francois, K., Hamoudi, W., Alkharty, M., Skripo, O., Uka, T.

Publikováno v: The Lancet Gastroenterology & Hepatology; April 2024, Vol. 9 Issue: 4 p366-382, 17p

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Autor: Öcal, Osman, Schinner, Regina, Schütte, Kerstin, de Toni, Enrico N., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J., Sengel, Christian, Bargellini, Irene, Gasbarrini, Antonio, Sangro, Bruno, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max, Kettner, E., Amthauer, H., Cwikla, J., Walecki, J., Klümpen, H., Schott, E., Kolligs, F., Rosmorduc, O., Menu, Y., Leroy, V., Mayerle, J., Trumm, C., Bartenstein, P., Reiser, M., Berg, T., Moche, M., Bilbao, I., Gossner, L., Reimer, P., Popovic, P., Stabuc, B., Piasecki, P., Podgajny, Z., Sacco, R., Peck-Radosavljevic, M., Lammer, J., Maleux, G., Verslype, C., Rosenberg, C., Nitsche, D., Waldenberger, P., Vergniol, J., Cassinotto, C., Yalcin, S., Peynircioglu, B., Zavaglia, C., Rampoldi, A., Tran, A., Chevallier, P., Anty, R., Trautwein, C., Kuhl, C., Grazioli, L., Vogl, T., Trojan, J., Bartolozzi, C., Iezzi, R., Bronowicki, J. P., Palmer, D., Evans, J., Sharma, R., Weir, G., Hubner, R., Basu, B., Ross, P.

Publikováno v: Cancer Imaging, Vol 22, Iss 1, Pp 1-13 (2022)
Cancer imaging, 22(1):1. BioMed Central Ltd.
Öcal, O, Schinner, R, Schütte, K, de Toni, E N, Loewe, C, van Delden, O, Vandecaveye, V, Gebauer, B, Zech, C J, Sengel, C, Bargellini, I, Gasbarrini, A, Sangro, B, Pech, M, Malfertheiner, P, Ricke, J, Seidensticker, M, SORAMIC study group, Kettner, E, Amthauer, H, Cwikla, J, Walecki, J, Klümpen, H, Schott, E, Kolligs, F, Rosmorduc, O, Menu, Y, Leroy, V, Mayerle, J, Trumm, C, Bartenstein, P, Reiser, M, Berg, T, Moche, M, Bilbao, I, Gossner, L, Reimer, P, Popovic, P, Stabuc, B, Piasecki, P, Podgajny, Z, Sacco, R, Peck-Radosavljevic, M, Lammer, J, Maleux, G, Verslype, C, Rosenberg, C, Nitsche, D, Waldenberger, P, Vergniol, J, Cassinotto, C, Yalcin, S, Peynircioglu, B, Zavaglia, C, Rampoldi, A, Tran, A, Chevallier, P, Anty, R, Trautwein, C, Kuhl, C, Grazioli, L, Vogl, T, Trojan, J, Bartolozzi, C, Iezzi, R, Bronowicki, J P, Palmer, D, Evans, J, Sharma, R, Weir, G, Hubner, R, Basu, B & Ross, P 2022, ' Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib ', Cancer imaging, vol. 22, no. 1, 1 . https://doi.org/10.1186/s40644-021-00439-x
Cancer Imaging
Cancer imaging 22, 1 (2022). doi:10.1186/s40644-021-00439-x
Cancer imaging, 22(1):1. e-med

Cancer imaging 22, 1 (2022). doi:10.1186/s40644-021-00439-x
Published by BioMed Central, London

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4729d698b2dfd43c9c1a684f537d6364

964P Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)

Autor: Peck Radosavljevic, M., Abdelgafur, A.M., Granito, A., Gasbarrini, A., Ma, Y., Mena, E., Lledó-Navarro, J.L., Presa, J., Weinmann, A., Levy, M.T., Pellicelli, A., Waldschmidt, D.T., Sørensen, H.T., Goyal, L., Ren, M., Saal, H., Okpara, C.E., Meyer, T.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S664-S664

The Influence of Portal Pressure on the Discordance Between Absolute CD4+ Cell Count and CD4+ Cell Percentage in HIV/Hepatitis C Virus—Coinfected Patients

Autor: Vienna HIV & Liver Study Group, Mandorfer, M., Reiberger, T., Payer, B. A., Peck-Radosavljevic, M.

Publikováno v: Clinical Infectious Diseases, 2013 Mar . 56(6), 904-905.

Externí odkaz: http://dx.doi.org/10.1093/cid/cis1017

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.